Clearside appoints George Lasezkay as a director

Clearside Biomedical (NASDAQ:CLSD) has appointed George Lasezkay to its board, replacing Derek Yoon.

In a statement, Christy Shaffer, chairperson of Clearside’s board, said Dr. Lasezkay has extensive executive leadership experience in the global ophthalmology, dermatology and medical aesthetics industries, playing a critical role in developing corporate strategy and providing counsel on strategic partnerships, business development programs and licensing transactions.  

Dr. Lasezkay has an accomplished history of success in the life sciences industry. For the past 15 years, he has served as an independent director on the boards of a number of domestic and foreign emerging biopharmaceutical companies, both public and private.  He currently serves on the board of directors of TheraVida, Inc., a clinical stage drug development company. Previously, Dr. Lasezkay served as Executive Vice President, General Counsel at Acucela Inc., a development stage company that specializes in identifying and developing novel ophthalmic therapeutics. For the 12 years prior to joining Acucela, he was President of Horizon Pharma Group, a private life sciences consultancy practice.  Prior to his private consultancy practice, Dr. Lasezkay was Corporate Vice President for Corporate Development at Allergan, Inc., the global pharmaceutical and medical aesthetics company.  His 13 years of progressive experience at Allergan includes a number of executive leadership positions, including being a member of the company’s Executive Committee, Assistant General Counsel for Commercial Affairs, and General Counsel for the Asia-Pacific Region. 

Earning a doctor of pharmacy degree from the State University of New York at Buffalo, and a J.D. degree from the Southern California Gould School of Law, Dr. Lasezkay also brings forward diverse knowledge and expertise in private firm and in-house legal practice, hospital pharmacy practice, clinical pharmacokinetics consultation and clinical drug research.